Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Nanoemulsion Technology Facilitates Drug Delivery

By Drug Discovery Trends Editor | May 14, 2010

nanobio.jpg

click to enlarge

Mechanism of action for nanoemulsion-based vaccines. (Source: NanoBio)

NanoBio Corporation is focused on developing and commercializing products based on its NanoStat technology. The platform provides the basis for therapeutic applications including intranasal vaccines (RSV, influenza), topical dermatological treatments (onychomycosis, acne), and anti-infectives (bacterial infections related to cystic fibrosis of the lung or COPD).

Clinical candidates derived from the NanoStat platform have shown activity against bacteria, viruses, fungi, and spores. A topical dermatological product derived from the platform works with nanoemulsion droplets that rapidly penetrate through pores and hair shafts to the site of the infection and physically disrupt the outer membrane of pathogenic organisms by fusing with and killing lipid-containing organisms. Unlike currently available therapies, NanoBio’s treatments are selectively toxic to microbes while non-irritating to skin and mucous membranes.1

In December 2009, NanoBio and GlaxoSmithKline plc (GSK) signed an exclusive licensing agreement in the United States. and Canada for the over-the-counter use of NanoBio’s investigational compound, NB-001, for the treatment of cold sores. NB-001 demonstrated clear efficacy and safety in randomized, double-blind, placebo-controlled Phase 2a and Phase 2b studies involving over 800 subjects with recurrent herpes labialis. In the Phase 2b study of 482 patients, NanoBio’s targeted Phase 3 topical dose healed patients 1.3 days faster than placebo. In both the 2a and 2b trials, NB-001 was well-tolerated with no safety concerns or adverse events reported. NanoBio is currently preparing to study the efficacy and safety of 0.3% NB-001 in two Phase 3 trials. GSK plans to build on its Abreva brand platform with NB-001.

NanoBio’s nanoemulsion-based intra-nasal vaccines are capable of permeating the nasal mucosa, where it loads vaccine antigen into immune-presenting cells. These cells then carry the antigen to areas of the body that initiate an immune response, including the lymph nodes, thymus, and spleen producing both mucosal immunity and systemic immune response. Virtually any bacterial or viral disease that results in a human immune response is a potential candidate for the development of a nanoemulsion-based mucosal vaccine. Active development programs are underway for influenza, respiratory syncytial virus, pneumococcal infection, hepatitis B, anthrax, smallpox, cancer, and other diseases.

NanoBio’s lead vaccine candidate, NB-1008, a seasonal influenza vaccine administered via a nasal dropper, has shown promising results in a recently completed Phase 1 clinical study. The results of the Phase 1 trial, combined with research efforts aimed at identifying the most viable nanoemulsion adjuvants, will guide the future development of nanoemulsion-based vaccines. However, data suggests that NanoBio’s treatment could play a key role in addressing pandemic situations by requiring far less antigen to elicit an immune response and also by potentially protecting against unanticipated strains of the virus. The company is currently in partnership discussions with several parties regarding NB-1008.

Reference
1. Hamouda T, Myc A, Donovan B, Shih A, Reuter J, Baker J, Jr. Novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. Microbiol Res. 2001;156(1):1-7.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50